此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

用于 ALS 的 AMX0035 的中等大小扩展访问协议

2026年11月8日 更新者:Amylyx Pharmaceuticals Inc.

提供 AMX0035、苯丁酸钠 (PB) 和牛磺熊二醇 (TURSO) 的固定组合,用于治疗肌萎缩性侧索硬化症 (ALS) 成年患者的中等大小、扩展访问协议

The Expanded Access Program will provide access and assess the safety of AMX0035 for the treatment of people living with ALS.

研究概览

地位

不再可用

干预/治疗

详细说明

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the endoplasmic reticulum (ER) and mitochondria. This Expanded Access Program is designed to provide expanded access to AMX0035 for the treatment of people living with ALS and assess safety in diverse populations/stages of ALS over 48 weeks.

研究类型

扩展访问

扩展访问类型

  • 中型人口

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • San Juan、波多黎各、00936
        • Hispanic Alliance for Research & Translational Research
    • California
      • Los Angeles、California、美国、90033
        • University of Southern California
      • Oakland、California、美国、94612
        • The Kaiser Permanente Medical Group
    • Florida
      • Fort Lauderdale、Florida、美国、33308
        • Holy Cross Health
      • Fort Lauderdale、Florida、美国、32608
        • Nova Southeastern University
      • Gainesville、Florida、美国、32608
        • University of Florida
    • Illinois
      • Chicago、Illinois、美国、60614
        • Northwestern University
    • Kansas
      • Kansas City、Kansas、美国、66103
        • University of Kansas Medical Center
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • The Sean M. Healey & AMG Center for ALS Massachusetts General Hospital
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic
    • Nebraska
      • Lincoln、Nebraska、美国、68510
        • Neurology Associates, P.C. / Somnos Clinical Research
    • New York
      • New York、New York、美国、10032
        • Columbia University Medical Center
    • North Carolina
      • Durham、North Carolina、美国、27705
        • Duke University Medical Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • University of Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • Thomas Jefferson University Weinberg ALS Center
    • Texas
      • El Paso、Texas、美国、79995
        • Texas Tech University Health Sciences Center El Paso
    • Virginia
      • Richmond、Virginia、美国、23298
        • Virginia Commonwealth University
    • Washington
      • Seattle、Washington、美国、98195
        • University of Washington School of Medicine
      • Seattle、Washington、美国、98122
        • Swedish Neuroscience Institute
      • Spokane、Washington、美国、99202
        • Providence St. Luke's Rehabilitation Medical Center
    • Wisconsin
      • Madison、Wisconsin、美国、53705
        • University of Wisconsin

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female, at least 18 years of age (inclusive);

  • Diagnosis of ALS made by a physician experienced with the management of ALS;

  • >36 months from symptom onset defined as first weakness

  • Capable of providing informed consent;

  • Capable of and willing to follow program procedures.

  • Participants who have established care with a physician experienced in treating patients with ALS involved in the program and will maintain this clinical care throughout the duration of their time in the program.

  • Women of childbearing potential (e.g., not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the program and 3 months after last dose of AMX0035;

    • Women must not be planning to become pregnant for the duration of the program and 3 months after last dose of study drug
  • Men must agree to practice contraception for the duration of the program and for at least 3 months after last dose of program drug;

    • Men must not plan to father a child or provide sperm

Exclusion Criteria

  • Currently enrolled in a therapeutic study involving the use of an investigational therapy;

  • Dependence on invasive mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at Screening;

    • No current need for tracheostomy or PAV (defined as more than 22 hours daily of mechanical ventilation for more than one week (7 days) or based on the site investigator's judgment; no need anticipated for the next 12 weeks
  • In the judgment of the Investigator, the participant's expected survival is less than 6 months

  • History of known allergy to the following: PB, bile salts, excipient/constituents of the formulation;

  • Abnormal liver function defined as AST and/or ALT >3 times the upper limit of the normal (obtained within 12 weeks from first dose);

  • Renal insufficiency as defined by eGFR <60 mL/min/1.73m2 (obtained within 12 weeks from first dose);

  • Pregnant women or women currently breastfeeding;

  • Current severe biliary disease which may result in the investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder;

  • History of Class III/IV heart failure (per New York Heart Association - NYHA);

  • Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Site Investigator clinical judgment;

  • Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed c consent, according to Site Investigator judgment;

  • Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the program, according to Site Investigator judgment;

  • Treatment, current or within 90 days from screening with any cell therapies or gene therapies;

  • Implantation of Diaphragm Pacing System (DPS);

  • Anything that, in the opinion of the Site Investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the program;

  • Current or planned exposure to any prohibited medications listed in Section 6.8.1 of the protocol

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究注册日期

首次提交

2022年3月9日

首先提交符合 QC 标准的

2022年3月9日

首次发布 (实际的)

2022年3月18日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月8日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅